Jin Medical International Completes VIE Deal and Expands Share Base in July 2026
I'm LongbridgeAI, I can summarize articles.Jin Medical International completed the acquisition of control over Beijing Tongsheng Technology via VIE agreements on July 21, 2026. The company issued over 70 million new Class A shares as consideration, expanding its share base to 78.4 million. This transaction, approved by shareholders, significantly alters the ownership structure and governance. Concurrently, the firm filed unaudited financial statements for the six months ended March 31, 2026, noting a recent 1-for-20 reverse share split.
The latest announcement is out from Jin Medical International Ltd. ( (ZJYL) ).
On August 4, 2026, Jin Medical International filed a Form 6-K with the U.S. Securities and Exchange Commission, releasing unaudited condensed consolidated financial statements for the six months ended March 31, 2026 and noting a recent 1-for-20 reverse share split that reshaped its capital base. The filing also recorded updated share counts and confirmed that semi-annual results would be communicated to investors through an accompanying press release.
The company reported completing on July 21, 2026 the contractual acquisition of control over Beijing Tongsheng Technology via VIE agreements through Erhua Medical Technology, after shareholder approvals at meetings held on July 20, 2026. As consideration, Jin Medical issued more than 64 million new Class A shares to the seller and over 6 million Class A shares to its financial adviser, expanded total ordinary shares outstanding to 78.4 million, and adopted a Third Amended and Restated Memorandum and Articles of Association, collectively signaling a significant shift in ownership structure and governance that will shape future consolidation and stakeholder dynamics.
More about Jin Medical International Ltd.
Jin Medical International Ltd., headquartered in Changzhou, Jiangsu Province, operates in the medical technology sector with a focus on mobility and rehabilitation products. The Cayman Islands–incorporated company accesses U.S. capital markets as a foreign private issuer and uses a dual-class share structure to manage control and investor participation.
The business leverages contractual arrangements in China to consolidate operating results from affiliated entities, reflecting a typical variable interest entity (VIE) structure among cross-border medical device manufacturers. This structure allows the group to benefit economically from onshore assets while complying with local regulatory constraints on foreign ownership in sensitive industries.
Average Trading Volume: 279,315
Technical Sentiment Signal: Strong Sell
Current Market Cap: $15.5M